Patents Examined by Jake Vu
  • Patent number: 10085947
    Abstract: An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: October 2, 2018
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Noreen Hassan
  • Patent number: 10039832
    Abstract: A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: August 7, 2018
    Assignee: UROGEN PHARMA LTD.
    Inventors: Asher Holzer, Dorit Daniel, Michael Mullerad, Jaime De La Zerda, Uri Shpolansky, Nadav Malchi, Yosh Dollberg, Dor Tal, Yossi Yavin, Marina Konorty
  • Patent number: 9988517
    Abstract: Microsphere compositions containing a mixture of at least two materials with same or differing phases are described. The materials have differing optical dispersion curves that intersect at at least one particular wavelength exhibiting the Christiansen effect. The materials may be encompassed by a microsphere, which may also include a separation entity.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: June 5, 2018
    Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventors: Sung-Wei Chen, Christopher J. Rothfuss
  • Patent number: 9962405
    Abstract: The present invention relates to an antiviral gel combination. The said gel is composed of a boron compound, and the poloxamer and chlorhexidine compounds; and the gel obtained with the present invention demonstrates high activity on Herpes Simplex Type 1 Virus (HSV).
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: May 8, 2018
    Assignee: YEDITEPE UNIVERSITESI
    Inventors: Fikrettin Sahin, Selami Demirci, Aysegul Dogan, Ayla Burcin Asutay
  • Patent number: 9956538
    Abstract: The invention relates to macro- and micro-liquid marbles (i.e. droplets of liquid with a particulate-based shell), and in particular, to photo-responsive macro- and micro-liquid marbles encapsulating a substance therein. Methods for forming the macro- and micro-liquid marbles, and use of the macro- and micro-liquid marbles, in controlled release applications are also disclosed.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: May 1, 2018
    Assignee: Agency for Science, Technology and Research
    Inventors: Jia Min Chin, Siok Wei Tay, Xiaobai Wang, Jianwei Xu, Andy Tzi Sum Hor
  • Patent number: 9950069
    Abstract: A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: April 24, 2018
    Assignee: UROGEN PHARMA LTD.
    Inventors: Asher Holzer, Dorit Daniel, Michael Mullerad, Jaime De La Zerda, Uri Shpolansky, Nadav Malchi, Yosh Dollberg, Dor Tal, Yossi Yavin, Marina Konorty
  • Patent number: 9937132
    Abstract: A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: April 10, 2018
    Assignee: DUCHESNAY INC.
    Inventors: Manon Vranderick, Jean-Luc St-Onge, Christelle Gedeon, Michele Gallo, Éric Gervais
  • Patent number: 9827335
    Abstract: The present application discloses treating water insoluble nanoparticles, particularly nanoparticles of metals and metal compounds which find utility in diagnostic imaging such as MR and X-ray imaging, with an alpha-hydroxyphosphonic acid conjugate with a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are ethylene oxide based polymers and copolymers and zwitterions and the nanoparticles are composed of transition metal oxides such as superparamagnetic iron oxide and tantalum oxide. Disclosed are nanoparticles which are sufficiently hydrophilic to form stable aqueous colloidal suspensions. Also disclosed is diagnostic imaging such as MR and X-ray using the modified hydrophilic nanoparticles as contrast agents.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: November 28, 2017
    Assignee: General Electric Company
    Inventors: Brian Christopher Bales, Bruce Allan Hay, Binil Itty Ipe Kandapallil
  • Patent number: 9795681
    Abstract: Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 24, 2017
    Assignee: Purdue Pharma L.P.
    Inventor: Osvaldo Abreu
  • Patent number: 9795571
    Abstract: A multi-particle dosage form that can deliver phenylephrine in controlled pulsed doses. The dosage form can contain an immediate release form that can contain phenylephrine or a salt thereof and a plurality of delayed release particles with a coating that can contain phenylephrine or salt thereof and a pH sensitive coating.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: October 24, 2017
    Assignee: The Procter & Gamble Company
    Inventors: Richard John Dansereau, Daren K. Anness, David L. Ramsey, Guhan Balan
  • Patent number: 9783562
    Abstract: The present invention provides: O-cyclic phytospingosine-1-phosphate (O-C-P1P), N-cyclic phytospingosine-1-phosphate (N-C-P1P), a pharmaceutically acceptable salt thereof, or a solvate thereof; a preparation method therefor; a cosmetic composition comprising the same for preventing hair loss or for growing hair; and a pharmaceutical composition for preventing and treating hair loss or for growing hair.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: October 10, 2017
    Assignee: PHYTOS CO., LTD
    Inventor: Myeong Jun Choi
  • Patent number: 9763466
    Abstract: A carbohydrate mixture for dietetic foods and pharmaceuticals is provided. The carbohydrate mixture comprises two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed. Carbohydrate component A may comprise at least one monosaccharide or of at least one oligosaccharide (disaccharide to hexasaccharide) or a mixture of two or more of these saccharides. Carbohydrate component B may comprise a polysaccharide (from heptasaccharide onwards) or a mixture of two or more polysaccharides. Carbohydrate component A=5 to 95 wt-% and carbohydrate component B=5 to 95 wt-% of the sum of the carbohydrate components A+B (=100 wt-%), and at least 80 wt-% of the carbohydrates/saccharides of both carbohydrate components have a prebiotic effect. The carbohydrate mixtures have not only a nutritive effect but they also stimulate health-promoting microorganisms present in the natural flora of the large intestine.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: September 19, 2017
    Assignee: N.V. Nutricia
    Inventors: Gunther Sawatzki, Bernd Stahl
  • Patent number: 9757342
    Abstract: The present invention relates to a method for preparing a protein cage which comprises: a 1st step of preparing an amphiphilic polymer comprising a 1st hydrophobic polymer and a 1st hydrophilic functional group; a 2nd step of preparing a hydrophilic protein comprising a 2nd functional group binding to the 1st functional group; a 3rd step of forming an amphiphilic polymer-protein hybrid by the binding of the 1st functional group and the 2nd functional group, and forming core-shell structured particles comprising a protein shell and an amphiphilic polymer core by the self-assembly of the amphiphilic polymer in a hydrophilic solvent; and a fourth step of removing some or all of the hydrophobic polymer of the core part from the core-shell structured particles.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: September 12, 2017
    Assignees: Pusan National University Industry-University Cooperation Foundation, Korea Research Institute of Chemical Technology, Gachon University of Industry-Academic Cooperation Foundation
    Inventors: Hyun Jong Paik, Jae Kwang Song, Seong Soo An, Chae Yeon Lee, Jong Hwa Jeong, Mohammad Abdul Kadir, Tae Heon Lee
  • Patent number: 9744252
    Abstract: The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (PET) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body. More particularly, the invention relates to small nonpeptide, high-affinity, specific-binding glycoprotein IIb/IIIa antagonists for imaging of thrombi.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 29, 2017
    Assignee: PIRAMAL IMAGING SA
    Inventors: Markus Berger, Martin Kruger, Jessica Lohrke, Michael Reinhardt, Holger Siebeneicher
  • Patent number: 9724417
    Abstract: Compositions are provided in which dendrimers and/or nanoparticles are synthesized with multi-photon responsive elements and self-immolative oligomers. The compositions may be utilized to selectively deliver Payloads within tissue by irradiating the compositions. The compositions may also be used to amplify sensitivity to irradiation.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: August 8, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Adah Almutairi, Nadezda Fomina, Jagadis Sankaranarayanan
  • Patent number: 9717673
    Abstract: The invention relates to shampoo preparations comprising water, an acrylic emulsion polymer and at least one surfactant. The preparations provide improved styling performance and improved hair feel.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: August 1, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Svenja Gschwind, Dirk Weber
  • Patent number: 9708364
    Abstract: A method for producing a capsule for protein crystallization is provided. The method comprises adding a solution containing a protein and a gelling agent to an ionic cross-linking solution to form an ionically cross-linked gel capsule that encapsulates a solution of the protein.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: July 18, 2017
    Assignee: RIKEN
    Inventor: Michihiro Sugahara
  • Patent number: 9693978
    Abstract: Liquid and semi-solid pharmaceutical compositions, which can be administered in liquid form or can be used for preparing capsules, are described herein. The composition comprises the salt of one ore more active agents, polyethylene glycol, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of active agent, and water. The pH of the composition is adjusted within the range of 2.5-7.5. The de-ionizing agent causes partial de-ionization (neutralization) of the salt of the active agent resulting in enhanced bioavailability of salts of weakly acidic, basic or amphoteric active agents as well as lesser amounts of polyethylene glycol (PEG) esters.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 4, 2017
    Assignee: Banner Life Sciences LLC
    Inventors: Nachiappan Chidambaram, Aqeel Fatmi
  • Patent number: 9693979
    Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: July 4, 2017
    Assignee: Banner Life Sciences LLC
    Inventors: Nachiappan Chidambaram, Aqeel A Fatmi
  • Patent number: 9687573
    Abstract: The present disclosure relates to polymeric materials that may be labeled with a radioisotope, to processes for producing the labeled polymeric material, and to methods of using the materials in analytical and therapeutic applications. Specifically, the disclosure relates to injectable and implantable microparticles, such as microspheres, which are associated with radioisotopes such that the microparticles are both therapeutic and detectable. The radioisotope-containing microparticles are useful for embolization and other therapeutic medical applications.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 27, 2017
    Assignee: Biosphere Medical, Inc.
    Inventors: Philippe Reb, Celine Chaix